Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

We have observed 5 EP applications Ian Gordon Berry has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12715421

THERAPEUTIC TREATMENT

IPC classification:
A61K 31/337, A61K 31/519, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Ian Gordon Berry, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP12717456

CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/5377, A61K 31/541, A61P 35/00, C07D 413/14, C07D 417/14
Applicant:
AstraZeneca AB
Agent:
Ian Gordon Berry, AstraZeneca PLC
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12759801

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

IPC classification:
A61K 31/437, A61K 31/506, A61P 35/00, C07D 401/02, C07D 471/04
Applicant:
AstraZeneca AB
Agent:
Ian Gordon Berry, AstraZeneca PLC
Status:
PATENT GRANTED
EP12727399

NOVEL TICAGRELOR CO - CRYSTAL

IPC classification:
A61K 31/519, A61P 7/02, C07D 487/04
Applicant:
AstraZeneca AB
Agent:
Ian Gordon Berry, AstraZeneca PLC
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14704881

COMBINATION THERAPY FOR THE TREATMENT OF NOSOCOMIAL PNEUMONIA

IPC classification:
A61K 31/4184, A61K 31/546, A61P 11/00
Applicant:
AstraZeneca AB
Agent:
Ian Gordon Berry, AstraZeneca PLC
Agent:
Pfizer
Status:
EXAMINATION IN PROGRESS

Please Sign in to use this feature